Morgan Stanley Neurocrine Biosciences Inc Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Morgan Stanley holds 1,573,297 shares of NBIX stock, worth $182 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,573,297
Previous 1,349,381
16.59%
Holding current value
$182 Million
Previous $155 Million
38.24%
% of portfolio
0.02%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
95.2MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.64 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.17 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$565 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$349 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$293 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...